Bristol-Myers Squibb Company Ce
Bristol-Myers Squibb Company Ce (CELG-RI) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
celg-ri · pe ratio · data through Dec 31, 2018
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Bristol-Myers Squibb Company Ce (CELG-RI) measures how much investors pay for each dollar of the company's trailing earnings. CELG-RI's current PE ratio of N/A is calculated by dividing its stock price of $0.11 by its TTM earnings per share of $5.51.
Source: FMP · /ratios-ttm · /analyst-estimates · 2018-12-31
PE Ratio History
2007 – 2018 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 11 fiscal years · Front-end computedMinQ1 · 25%24.1x
MedianQ3 · 75%59.2x
Max
At N/A, CELG-RI's current P/E is lower than in 0% of its annual fiscal year readings over the past 11 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - General · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Bristol-Myers Squibb Company CeYou CELG-RI | $224M | N/A | — | $5.51 |
 Amgen Inc. AMGN | $186.6B | 22.84x | -3.8% | $14.33 |
 CVS Health Corporation CVS | $123.9B | 56.87x | +139.6% | $1.40 |
 Gilead Sciences, Inc. GILD | $159.0B | 17.94x | -24.4% | $6.84 |
 GSK plc GSK | $101.8B | 6.45x | -72.8% | $5.64 |
 HCA Healthcare, Inc. HCA | $80.2B | 15.88x | -33.1% | $29.40 |
 McKesson Corporation MCK | $92.2B | 22.46x | -5.4% | $38.53 |
Industry Average 6 peers with valid PE | — | 23.74x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2018-12-31Latest FY2018 | 11.62x | $5.51 | -58.0% | |
2017-12-31 FY2017 | 27.66x | $3.77 | -38.5% | |
2016-12-31 FY2016 | 45.00x | $2.57 | -24.0% | |
2015-12-31 FY2015 | 59.22x | $2.02 | +31.9% | |
2014-12-31 FY2014 | 44.90x | $2.49 | +86.2% | |
2013-12-31 FY2013 | 24.11x | $3.50 | +107.7% | |
2012-12-31 FY2012 | 11.61x | $3.38 | -0.6% | |
2011-12-31 FY2011 | 11.68x | $2.89 | -24.8% | |
2010-12-31 FY2010 | 15.53x | $1.90 | -5.7% | |
2009-12-31 FY2009 | 16.46x | $1.69 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Bristol-Myers Squibb Company Ce (CELG-RI) measures how much investors pay for each dollar of the company's trailing earnings. CELG-RI's current PE ratio of N/A is calculated by dividing its stock price of $0.11 by its TTM earnings per share of $5.51.
Frequently asked questions
CELG-RI pe ratio · 6 questionsCELG-RI's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.11 and TTM EPS of $5.51. Data sourced from Financial Modeling Prep via CELG-RI's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Bristol-Myers Squibb Company Ce SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08